Rocío Lledó‐García

The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study

Rocío Lledó‐García, Shikiko Watanabe, Grant Langdon et al. · Science Translational Medicine · 2017 · 195 citations

Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration

Bryan Smith, Rocío Lledó‐García, Kate L. Dixon et al. · mAbs · 2018 · 110 citations · Full text

Immunocytochemical Technique, Immunotoxicology, Antibody Isolation +18

A semi-mechanistic model of the relationship between average glucose and HbA1c in healthy and diabetic subjects

Rocío Lledó‐García, Norman A. Mazer, Mats O. Karlsson · Journal of Pharmacokinetics and Pharmacodynamics · 2013 · 33 citations

Metabolic Syndrome, Diabetes Management, Insulin Management +12

Modeling of red blood cell life-spans in hematologically normal populations

Rocío Lledó‐García, Robert M. Kalicki, Dominik E. Uehlinger et al. · Journal of Pharmacokinetics and Pharmacodynamics · 2012 · 22 citations · Full text

Bone Marrow Failure, Heme Homeostasis, Longevity +8

Safety, pharmacokinetics, and pharmacodynamics of epratuzumab in Japanese patients with moderate-to-severe systemic lupus erythematosus: Results from a phase 1/2 randomized study

Tomomi Tsuru, Yoshiya Tanaka, Mitsumasa Kishimoto et al. · Modern Rheumatology · 2015 · 19 citations · Full text